Treatment of Metabolic (Dysfunction)-Associated Fatty Liver Disease: Evidence from Randomized Controlled Trials—A Short Review DOI
Konstantinos Kitsios, Christina Trakatelli, Christina Antza

и другие.

Metabolic Syndrome and Related Disorders, Год журнала: 2024, Номер unknown

Опубликована: Авг. 1, 2024

Metabolic-associated fatty liver disease (MALFD) is a highly prevalent and progressive disease, strongly related to obesity, metabolic syndrome, cardiovascular disease. It comprises spectrum of pathology from steatosis (fat accumulation in the hepatocytes) with inflammation (metabolic-associated steatohepatitis, MASH), fibrosis, cirrhosis, hepatocellular carcinoma. There currently only one medication, resmetirom, US Food Drug Administration approved for treatment MALFD. Evidence randomized trials supports efficacy hypocaloric diets exercise MASH resolution. Moreover, substantial weight loss after bariatric surgery can lead significant longitudinally sustained resolution, improvement decrease risk major adverse events. Pioglitazone, an insulin sensitizer, initiated at early stages, before progression may be effective resolution patients or without type 2 diabetes. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), semaglutide liraglutide, also but not fibrosis. Preliminary data interventions tirzepatide, dual GLP-1 glucose-dependent insulinotropic polypeptide RA, sodium-glucose cotransporter inhibitors are encouraging, more based on biopsy needed.

Язык: Английский

Lingguizhugan decoction enhances autophagy of Alzheimer’s disease via regulating the mTOR/ p70s6K pathway in vivo and in vitro DOI Creative Commons
Xiaojing Chen,

Q. Tian,

Min Gao

и другие.

Frontiers in Aging Neuroscience, Год журнала: 2025, Номер 17

Опубликована: Янв. 22, 2025

Introduction Lingguizhugan decoction (LGZG) has been reported to treat Alzheimer’s disease (AD) by anti-inflammatory and transporting amyloid-β (Aβ). Methods Using APP/PS1 transgenic mice as in vivo model gave LGZG oral gavage. Aβ 25-35 -induced SH-SY5Y cells vitro then added medicated serum (LMS) observe the regulatory effect of on AD autophagy-related pathways. Morris water maze (MWM) was used evaluate mice’s learning memory ability. Mice’s hippocampus tissue sections were stained immunohistochemically hippocampal deposition. Transmission electron microscopy monitored autophagosomes autolysosomes. Western blot analysis measured protein expression levels beclin-1, p62 light chain 3II (LC3 II) mTOR signaling. Results: could greatly improve ability mice, enhance autophagy . increased beclin-1 LC3 II decreased p62. Conclusion enhanced showed therapeutic potential inhibiting mTOR/p70s6K

Язык: Английский

Процитировано

1
Treatment of Metabolic (Dysfunction)-Associated Fatty Liver Disease: Evidence from Randomized Controlled Trials—A Short Review DOI
Konstantinos Kitsios, Christina Trakatelli, Christina Antza

и другие.

Metabolic Syndrome and Related Disorders, Год журнала: 2024, Номер unknown

Опубликована: Авг. 1, 2024

Metabolic-associated fatty liver disease (MALFD) is a highly prevalent and progressive disease, strongly related to obesity, metabolic syndrome, cardiovascular disease. It comprises spectrum of pathology from steatosis (fat accumulation in the hepatocytes) with inflammation (metabolic-associated steatohepatitis, MASH), fibrosis, cirrhosis, hepatocellular carcinoma. There currently only one medication, resmetirom, US Food Drug Administration approved for treatment MALFD. Evidence randomized trials supports efficacy hypocaloric diets exercise MASH resolution. Moreover, substantial weight loss after bariatric surgery can lead significant longitudinally sustained resolution, improvement decrease risk major adverse events. Pioglitazone, an insulin sensitizer, initiated at early stages, before progression may be effective resolution patients or without type 2 diabetes. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), semaglutide liraglutide, also but not fibrosis. Preliminary data interventions tirzepatide, dual GLP-1 glucose-dependent insulinotropic polypeptide RA, sodium-glucose cotransporter inhibitors are encouraging, more based on biopsy needed.

Язык: Английский

Процитировано

2